143
Participants
Start Date
January 8, 2021
Primary Completion Date
November 1, 2022
Study Completion Date
February 20, 2024
Artemether-lumefantrine (AL)
Current first line treatment of malaria. Dose: Bodyweight (kg) Dose (mg) of artemether + lumefantrine given twice daily for 3 days (total, six doses) 5 to \< 15 20 + 120 15 to \< 25 40 + 240 25 to \< 35 60 + 360 \>=35 80 + 480; Twice daily for 3 days (total, six doses)
Pyronaridine-artesunate (PA)
Antimalarial; Dose: Body weight (kg) Dose (mg) of pyronaridine + aresunate given once daily for 3 days (total, three doses) 5 to \< 8 60 + 20 8 to \<15 120 + 40 15 to \<20 180 + 60 20 to \<24 kg 180 + 60 24 to \<45 360 + 120 45 to \<65 540 + 180 \>=65 720 + 240; Once-daily for 3 days (total, three doses).
Kisumu County Referral Hospital, Kisumu
Ouagadougou Hospitals, Ouagadougou
Collaborators (1)
London School of Hygiene and Tropical Medicine
OTHER
Kenya Medical Research Institute
OTHER
Groupe de Recherche Action en Sante
OTHER
Centres for Disease Control and Prevention, Kenya.
OTHER
Bill and Melinda Gates Foundation
OTHER
Centers for Disease Control and Prevention
FED
Liverpool School of Tropical Medicine
OTHER